Sinan Abuzaid

Sinan Abuzaid

Auto-generated profile, based on publicly available information

Sinan Abuzaid

Herbert Irving Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 May 2024 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
ZWZachary H. Walsh
Zachary H. Walsh
PSParin Shah
Parin Shah
NKNeeharika Kothapalli
Neeharika Kothapalli
SSShivem B. Shah
Shivem B. Shah
GNGergo Nikolenyi
Gergo Nikolenyi
BIBenjamin Izar
Benjamin Izar

27 October 2025 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
MHMorteza Chalabi Hajakrim
Morteza Chalabi Hajakrim
MMMichael May
Michael May
AAAmit Dipak Amin
Amit Dipak Amin
JJJacob Jamison
Jacob Jamison
STSomnath Tagore
Somnath Tagore
BIBenjamin Izar
Benjamin Izar

31 July 2024 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
KLKaran Luthria
Karan Luthria
PSParin Shah
Parin Shah
BCBlake Caldwell
Blake Caldwell
JMJohannes C. Melms
Johannes C. Melms
SASinan Abuzaid
Sinan Abuzaid
BIBenjamin Izar
Benjamin Izar
Purpose: Sarcoma encompasses a diverse group of cancers that are typically resistant to current therapies, including immune checkpoint blockade (ICB), and underlying mechanisms are poorly understood. The contexture of sarcomas limits generation of high-quality data using cutting-edge molecular profiling methods, such as single-cell RNA-sequencing, thus hampering progress in understanding these understudied cancers. Experimental Design: Here, we demonstrate feasibility of producing multimodal single-cell genomics and whole-genome sequencing data from frozen tissues, profiling 75,716 cell transcriptomes of five undifferentiated pleomorphic sarcoma and three intimal sarcoma samples, including paired specimens from two patients treated with ICB. Results: We find that genomic diversity decreases in patients with response to ICB, and, in unbiased analyses, identify cancer cell programs associated with therapy resistance. Although interactions of tumor-infiltrating T lymphocytes within the tumor ecosystem increase in ICB responders, clonal expansion of CD8+ T cells alone was insufficient to predict drug responses. Conclusions: This study provides a framework for studying rare tumors and identifies salient and treatment-associated cancer cell intrinsic and tumor microenvironmental features in sarcomas.

1 June 2026 in JCO Precision Oncology
Verified
Journal Article
Closed access
BLBrian W. Labadie
Brian W. Labadie
AOAleksandar Obradovic
Aleksandar Obradovic
ARAlexander G. Raufi
Alexander G. Raufi
UWUrszula N. Wasko
Urszula N. Wasko
LTLorenzo Tomassoni
Lorenzo Tomassoni
GMGulam A. Manji
Gulam A. Manji
PURPOSE: Combined mitogen-activated protein kinase kinase (MEK) and autophagy inhibition has shown antitumor efficacy in preclinical pancreatic ductal adenocarcinoma (PDAC) models. We evaluated this therapeutic strategy in the autochthonous K-ras LSL.G12D/+ ; Trp53 R172H/+ ; Pdx-1-Cre (KPC) mouse model and in the MEKiAUTO phase I trial of patients with metastatic KRAS -mutant PDAC, with or without anti–PD-L1 antibody atezolizumab. Methods: Short-term intervention studies in KPC mice and a phase I clinical trial based on a time-to-event continual reassessment method design were performed. Tumor response was assessed through multiplex immunofluorescence, reverse-phase protein array, and single-nucleus RNA sequencing of serial tumor specimens. RESULTS: MEK and autophagy inhibition suppressed tumor growth in KPC mice. In the clinical trial, 14 patients were treated and four experienced a dose-limiting toxicity. The median progression-free survival (PFS) and overall survival were 7.7 weeks (95% CI, 6 to 15.6) and 20.7 weeks (95% CI, 15.6 to 46.1), respectively. snRNA-seq on paired tumor biopsies identified substantial malignant cell heterogeneity, including an epithelial subtype enriched for autophagy and mitogen-activated protein kinase (MAPK) signaling that decreased after treatment. Higher baseline abundance of this subtype correlated with longer PFS but was rare in TCGA PDAC tumors. By contrast, KPC tumors and PDAC cell lines exhibited reduced heterogeneity and uniform enrichment of this MAPK/autophagy-high state, consistent with their stronger preclinical responses. CONCLUSION: Combined MEK and autophagy inhibition showed limited tolerability in human PDAC. Divergent efficacy between preclinical and clinical settings likely reflects differences in tumor cell state heterogeneity between models. Integration of diverse, representative preclinical models is critical to guide development of effective therapies in PDAC.

1 October 2024
Verified
Other
Open access
KLKaran Luthria
Karan Luthria
PSParin Shah
Parin Shah
BCBlake Caldwell
Blake Caldwell
JMJohannes C. Melms
Johannes C. Melms
SASinan Abuzaid
Sinan Abuzaid
BIBenjamin Izar
Benjamin Izar
Supplemental Table 2: Pathway enrichment analyses for indicated samples.

1 October 2024
Verified
Other
Open access
KLKaran Luthria
Karan Luthria
PSParin Shah
Parin Shah
BCBlake Caldwell
Blake Caldwell
JMJohannes C. Melms
Johannes C. Melms
SASinan Abuzaid
Sinan Abuzaid
BIBenjamin Izar
Benjamin Izar
Violin plots and boxplots displaying the (a) genes detected per cell and (b) stress signature expression per cell and (c) mitochondrial fraction of reads in samples profiled from fresh or frozen tissue in this study and in indicated studies by Jerby et. al. (dijon) and Slyper et al. (green), respectively. The upper and lower edges of the boxplot display the 75th and 25th percentiles respectively. Blue violin plots are from scRNA-seq from fresh tissue, and red violin plots are from snRNA-seq on frozen tissue.